Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of temsirolimus and irinotecan in treatment-resistant metastatic colorectal cancer with KRAS mutations
2008-007665-22Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temsirolimus and irinotecan in colorectal cancer (CRC) (2 arms), sponsored by Vejle Hospital. Primary endpoint: Objective response rate by RECIST. Started Dec 2008; status: completed.
02
Drugs
temsirolimusirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2008-007665-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007665-22.